secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2026-09-10T10:02:31+00:00
Accession:  0001628280-26-061208
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen acquires BioCircuit for $200M cash, funds via $208.7M stock offering
---------------------------------------------------------------------------

- Acquires BioCircuit for $200M cash; $1M withheld for post-closing adjustments; close expected Q4 2026.
- Adds NerveTape, first FDA-approved sutureless nerve repair device; spin-out of BioCircuit's electronics business before close.
- Priced 4.91M shares at $42.50/share for ~$208.7M gross; underwriters have 30-day option for 736,500 more.
- Deal expected accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in first year post-close.
- No regulatory approvals required; financing not conditioned on deal; if deal fails, proceeds for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000162828026061208/0001628280-26-061208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000162828026061208/axgn-20260909.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-061208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer